Ensysce Biosciences, Inc. ENSC
0.41
0.01
2.50%
as of 25 Sep
- Market cap
- $7.8M
- P/E
- 0.0×
Follow ENSC
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (1,295.01%) | (1,149.06%) | (324.86%) | (294.39%) |
+8 more TTM periods Free account |
|
| (295.92%) | (347.70%) | (155.95%) | (174.66%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
1,136.46% | 1,658.44% | (363.24%) | (1,468.48%) | |
Average Days of Receivables |
33.80 | 0.00 | 30.28 | 0.36 | |
Free Cash Flow per Share |
(0.68) | (1.40) | (3.05) | (2.44) | |
Free Cash Flow |
(8.86) | (9.60) | (7.81) | (7.04) | |
Piotroski F-Score |
1.00 | 2.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
2,039.94% | (12,548.76%) | (108.49%) | (276.49%) | |
Accounts Receivable Turnover |
20.51 | 0.00 | 18.61 | 5.02 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
275.21% | 251.46% | 204.81% | 235.44% | |
Selling, General and Administrative Expense of Revenue |
106.11% | 99.94% | 97.32% | 110.45% | |
Share Based Compensation of Revenue |
(0.34%) | 3.60% | 3.50% | 4.07% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.70 | 0.81 | 0.77 | 0.64 | |
Depreciation/Fixed assets |
0.18 | 0.11 | 0.26 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Revenue per Share |
0.35 | 0.69 | 1.98 | 1.56 | |
Operating CF per Share |
(0.68) | (1.40) | (3.05) | (2.44) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(280.49%) | (250.36%) | (200.84%) | (244.49%) |
Columns are period end dates